2022-10-27 16:00Financial Performance - The company's revenue for Q3 2022 reached ¥219,260,922.75, representing a year-over-year increase of 162.30%[4] - Total operating revenue for the first three quarters of 2022 reached RMB 569,635,902.97, a significant increase from RMB 114,506,776.26 in the same period of 2021, representing a growth of approximately 397.5%[19] - The total profit (loss) for Q3 2022 was -688,219,233.92 RMB, compared to -688,259,394.55 RMB in the previous period[20] - The net profit (loss) attributable to shareholders of the parent company was -688,219,233.92 RMB, consistent with the previous period[20] - The total comprehensive income for Q3 2022 was -680,108,752.02 RMB, compared to -688,616,249.38 RMB in the previous period[20] Profitability and Loss - The net profit attributable to shareholders was -¥199,094,007.06, with a year-to-date net profit of -¥688,219,233.92[4] - The basic and diluted earnings per share for the quarter were both -¥0.37, with a year-to-date figure of -¥1.32[5] - The basic and diluted earnings per share for Q3 2022 were both -1.32 RMB, compared to -1.41 RMB in the previous period[20] - The company reported a net loss of RMB 1,031,670,017.72 for the first three quarters of 2022, compared to a net loss of RMB 343,450,783.80 in the same period of 2021[18] Research and Development - R&D expenses totaled ¥212,869,547.05 for the quarter, accounting for 97.09% of revenue, a decrease of 139.80 percentage points compared to the same period last year[5] - The company plans to continue its R&D activities, despite the high proportion of R&D expenses relative to revenue[8] - Research and development expenses for the first three quarters of 2022 amounted to RMB 662,541,383.59, up from RMB 524,624,528.96 in 2021, reflecting a growth of approximately 26.3%[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,971,303,165.55, reflecting a 43.57% increase from the end of the previous year[5] - The company's total assets as of September 30, 2022, were RMB 5,971,303,165.55, compared to RMB 4,159,208,876.60 at the end of 2021, marking an increase of about 43.5%[18] - The total liabilities as of September 30, 2022, were RMB 703,549,537.44, slightly down from RMB 712,787,425.02 in the previous year[18] - The total equity attributable to shareholders as of September 30, 2022, was RMB 5,267,753,628.11, compared to RMB 3,446,421,451.58 at the end of 2021, representing an increase of about 52.9%[18] Cash Flow - The company reported a net cash flow from operating activities of -¥1,080,292,854.28 for the year-to-date period[5] - Cash inflow from operating activities for the first three quarters of 2022 was 374,115,692.77 RMB, up from 235,496,564.18 RMB in the same period of 2021[22] - Cash outflow from operating activities totaled 1,454,408,547.05 RMB, compared to 955,305,059.59 RMB in the previous year[22] - The net cash flow from operating activities for the first three quarters of 2022 was 1,080,292,854.28 RMB[22] - Cash inflow from investment activities was 685,653,675.14 RMB, compared to 86,580,323.21 RMB in the previous year[22] - Cash inflow from financing activities was 2,612,462,448.00 RMB, with a net cash flow of 2,438,024,300.14 RMB[22] - The ending cash and cash equivalents balance was 1,967,108,319.61 RMB, compared to 1,003,253,752.77 RMB in the previous period[23] Inventory and Other Metrics - The company's inventory as of September 30, 2022, was RMB 442,285,036.79, an increase from RMB 280,314,179.90 in 2021, indicating a growth of approximately 57.8%[17] - The company's cash and cash equivalents increased to RMB 2,034,818,774.76 as of September 30, 2022, from RMB 1,835,498,496.42 at the end of 2021, showing a growth of approximately 10.9%[17] - The equity attributable to shareholders increased to ¥5,267,753,628.11, a rise of 52.85% compared to the previous year[5] - The company has not reported any significant new product launches or market expansions during the reporting period[16] Revenue Drivers - The increase in revenue was primarily driven by the inclusion of certain products in the national medical insurance directory, leading to increased sales volume[8] - The company experienced a significant increase in technical service revenue from Seagen, contributing to overall revenue growth[8]